tetano
Editor, Senior Moderator
Hum Immunol
. 2021 Jul 1;S0198-8859(21)00174-9.
doi: 10.1016/j.humimm.2021.06.011. Online ahead of print.
Humoral immune mechanisms involved in protective and pathological immunity during COVID-19
Gunawan Widjaja[SUP] 1 [/SUP], Abduladheem Turki Jalil[SUP] 2 [/SUP], Heshu Sulaiman Rahman[SUP] 3 [/SUP], Walid Kamal Abdelbasset[SUP] 4 [/SUP], Dmitry O Bokov[SUP] 5 [/SUP], Wanich Suksatan[SUP] 6 [/SUP], Mahnaz Ghaebi[SUP] 7 [/SUP], Faroogh Marofi[SUP] 8 [/SUP], Jamshid Gholizadeh Navashenaq[SUP] 9 [/SUP], Farhad Jadidi-Niaragh[SUP] 10 [/SUP], Majid Ahmadi[SUP] 11 [/SUP]
Affiliations
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 is associated with excessive inflammation, as a main reason for severe condition and death. Increased inflammatory cytokines and humoral response to SARS-CoV-2 correlate with COVID-19 immunity and pathogenesis. Importantly, the levels of pro-inflammatory cytokines that increase profoundly in systemic circulation appear as part of the clinical pictures of two overlapping conditions, sepsis and the hemophagocytic syndromes. Both conditions can develop lethal inflammatory responses that lead to tissue damage, however, in many patients hemophagocytic lymphohistiocytosis (HLH) can be differentiated from sepsis. This is a key issue because the life-saving aggressive immunosuppressive treatment, required in the HLH therapy, is absent in sepsis guidelines. This paper aims to describe the pathophysiology and clinical relevance of these distinct entities in the course of COVID-19 that resemble sepsis and further highlights two effector arms of the humoral immune response (inflammatory cytokine and immunoglobulin production) during COVID-19 infection.
Keywords: 2019 novel coronavirus disease (COVID-19); Antibody response; Hemophagocytic lymphohistiocytosis (HLH); Sepsis; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
. 2021 Jul 1;S0198-8859(21)00174-9.
doi: 10.1016/j.humimm.2021.06.011. Online ahead of print.
Humoral immune mechanisms involved in protective and pathological immunity during COVID-19
Gunawan Widjaja[SUP] 1 [/SUP], Abduladheem Turki Jalil[SUP] 2 [/SUP], Heshu Sulaiman Rahman[SUP] 3 [/SUP], Walid Kamal Abdelbasset[SUP] 4 [/SUP], Dmitry O Bokov[SUP] 5 [/SUP], Wanich Suksatan[SUP] 6 [/SUP], Mahnaz Ghaebi[SUP] 7 [/SUP], Faroogh Marofi[SUP] 8 [/SUP], Jamshid Gholizadeh Navashenaq[SUP] 9 [/SUP], Farhad Jadidi-Niaragh[SUP] 10 [/SUP], Majid Ahmadi[SUP] 11 [/SUP]
Affiliations
- PMID: 34229864
- DOI: 10.1016/j.humimm.2021.06.011
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 is associated with excessive inflammation, as a main reason for severe condition and death. Increased inflammatory cytokines and humoral response to SARS-CoV-2 correlate with COVID-19 immunity and pathogenesis. Importantly, the levels of pro-inflammatory cytokines that increase profoundly in systemic circulation appear as part of the clinical pictures of two overlapping conditions, sepsis and the hemophagocytic syndromes. Both conditions can develop lethal inflammatory responses that lead to tissue damage, however, in many patients hemophagocytic lymphohistiocytosis (HLH) can be differentiated from sepsis. This is a key issue because the life-saving aggressive immunosuppressive treatment, required in the HLH therapy, is absent in sepsis guidelines. This paper aims to describe the pathophysiology and clinical relevance of these distinct entities in the course of COVID-19 that resemble sepsis and further highlights two effector arms of the humoral immune response (inflammatory cytokine and immunoglobulin production) during COVID-19 infection.
Keywords: 2019 novel coronavirus disease (COVID-19); Antibody response; Hemophagocytic lymphohistiocytosis (HLH); Sepsis; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).